The common side effects of oxymetholone include depression , lethargy , headache , swelling , rapid weight gain , priapism , changes in skin color, urination problems, nausea , vomiting , stomach pain (if taken on an empty stomach), loss of appetite , jaundice , breast swelling in men, feeling restless or excited, insomnia , and diarrhea .  In women, side effects also include acne , changes in menstrual periods , voice deepening , hair growth on the chin or chest , pattern hair loss , enlarged clitoris , and changes in sex drive .   Because of its 17α-alkylated structure, oxymetholone is hepatotoxic .  Long term use of the drug can cause a variety of serious ailments, including hepatitis , liver cancer , and cirrhosis ; therefore periodic liver function tests are recommended for those taking oxymetholone. 
Awareness and educational efforts are working to help prevent anabolic steroid abuse in schools and communities. The Adolescents Training and Learning to Avoid Steroids (ATLAS) and the Athletes Targeting Healthy Exercise and Nutrition Alternatives (ATHENA) programs, funded by the NIDA, and supported by the Oregon Health & Science University programs is teaching athletes that they do not need steroids to build powerful muscles and improve athletic performance. These programs provide weight-training and nutrition alternatives, increase healthy behaviors, less likelihood to try steroids, and less likelihood to engage in other dangerous behaviors such as drinking and driving, use of marijuana and alcohol , and and improved body image. Bother Congress and the Substance Abuse and Mental Health Services Administration endorsed these model prevention programs. 4
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .